$147 million Australian and most of this should fall straight to the bottom line. This alone is worth todays shareprice. @Nnyck777 and @mikebrisy as of a few mintues ago I have now joined you both as shareholders.

I also came across this physician video from the Neuren linkedin feed. From this it sounds like not all Rhetts patients will be suitable for DayBue, but it does sound like the ones who are and tolerate the drug will be on it for life. From this it is unlikely to be a winner takes all market and their could be room for Anavex and DayBue to complement each other in terms of patient need/response. I am comfortable with a total patient target pool for DayBue of being closer to 2500 than the 5-10K, but I think the numbers still work well at this level.